Developing invention, attracting inward expenditure, creating new jobs and economic growth are aspirations for us all and we think that the chances of success are better through an authentic partnership approach. Using the comparative advantages of Essex within an internationally focused partnership will convert aspiration into tangible financial success for the benefit of UK plc. This partnership will support the existing MedTech cluster and the culture of scientific business and innovation within the town. This means industry can engage with local authorities and treatment commissioners in a new way to deliver proper care innovatively.Related StoriesWyss Institute, UMass synergy to develop drug-device mixture for treating bloodstream clots in stroke patientsPacemakers can identify AF and enable initiation of anticoagulation for stroke preventionMeta-evaluation backs thrombectomy over regular stroke careAs reported in JAMA, there is also no difference between beta-blocker users and nonusers among CAD patients with out a background of MI not. Nevertheless, 1101 of CAD sufferers without MI who used beta blockers experienced the principal composite outcome plus hospitalization for atherothrombotic events or revascularization – the secondary outcome – weighed against 1002 of these who didn’t.